Alpha Cognition Inc. Stock-Based Compensation
Alpha Cognition Inc. (ACOG) reported Stock-Based Compensation of $2.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Alpha Cognition Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.45M, a 4.57% increase year-over-year.
- Alpha Cognition Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.40M, a 24.09% increase year-over-year.
- Alpha Cognition Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $945.50K, a 340.78% increase year-over-year.
- Alpha Cognition Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.46M, a 652.33% increase year-over-year.
- Alpha Cognition Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $4.92M, a 334.98% increase from fiscal 2024.
- Alpha Cognition Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $1.13M, a 52.24% decline from fiscal 2023.
- Alpha Cognition Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $2.37M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.86M 10-Q · filed 2026-08-13 | $3.80M derived: sum of 3 quarters · filed 2026-08-13 | $5.26M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $1.40M 10-Q · filed 2026-05-14 | $2.35M derived: sum of 2 quarters · filed 2026-05-14 | $3.81M derived: sum of 3 quarters · filed 2026-05-14 | $5.19M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $945.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.40M derived: sum of 2 quarters · filed 2026-03-31 | $3.79M derived: sum of 3 quarters · filed 2026-08-13 | $4.92M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.85M derived: sum of 2 quarters · filed 2026-08-13 | $3.98M 10-Q · filed 2025-11-13 | $4.19M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.52M 10-Q · filed 2026-08-13 | $2.90M 10-Q · filed 2025-08-14 | $2.73M derived: sum of 3 quarters · filed 2026-08-13 | $2.93M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $1.13M 10-Q · filed 2026-05-14 | $1.36M 10-Q · filed 2025-05-15 | $1.35M derived: sum of 2 quarters · filed 2026-05-14 | $1.54M derived: sum of 3 quarters · filed 2026-05-14 | $1.91M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $214.51K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $408.25K derived: sum of 2 quarters · filed 2026-03-31 | $783.58K derived: sum of 3 quarters · filed 2026-03-31 | $1.13M 10-K · filed 2026-03-31 | $979.80K 10-K · filed 2025-03-31 | ||
| 2024-09-30 | $193.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $569.07K derived: sum of 2 quarters · filed 2025-11-13 | $917.15K 10-Q · filed 2025-11-13 | $1.39M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $375.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $723.41K 10-Q · filed 2025-08-14 | $1.19M derived: sum of 3 quarters · filed 2025-08-14 | $1.89M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $348.08K 10-Q · filed 2025-05-15 | $818.24K derived: sum of 2 quarters · filed 2025-05-15 | $1.52M derived: sum of 3 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $470.16K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.17M derived: sum of 2 quarters · filed 2025-03-31 | $2.37M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $697.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.90M 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | $1.20M 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |